Sixteen startup teams pitched at the seventh annual — but first-ever virtual – Bayou Startup Showcase. Photo courtesy of OwlSpark and RED Labs

Even despite a global pandemic, two university-based summer startup accelerator programs were determined to continue on. And, that's exactly what they did.

University of Houston's RED Labs and Rice University's OwlSpark pivoted their summer program, which they put on collaboratively, to a virtual approach. On Thursday, August 6, the program's 16 startup teams pitched their projects at the seventh annual Bayou Startup Showcase.

Here are this year's Class 8 presentations:

EVA

Vascular access requires a medical team to use an ultrasound machine to help navigate a needle's precision during the procedure. However, 5 percent of procedures result in an inexact and painful outcome. OwlSpark company, EVA — which stands for Exact Vascular Access, has created a device that works with the ultrasound machine to endure navigation of the needle during the procedure.

CareSafe

Seven million people fall every year, but as great and helpful wearable devices are, they aren't foolproof. CareSafe, a RED Labs company, taps into home WiFi to visualize when a fall occurs and the company can even notify emergency contacts and emergency services.

Ai-Ris

People who live in underserved and rural areas don't have regular access to eye care — which means that these people are exposed to preventable eye diseases. Ai-Ris has created a portable, telemedicine-ready device that can help get these populations access to eye care.

Dividends360

Ninety million people invest in the stock market — and more than half of those investors are self directed and spending several hours a week on planning their investments. RED Labs company Dividends360 is a web-based platform to help the modern investor make his or her decisions in a more efficient way.

FirstGen Solutions

Expecting mothers can't take the majority of medications in the market because the effects of the chemicals on the unborn child is unknown, and testing is limited to costly, inaccurate, and highly regulated animal testing. FirstGen Solutions, an OwlSpark company, is producing a stem cell testing kit for pharmaceutical companies to use as an earlier and easier way to indicate potential risks a medicine could have.

nisa EFFECT

Women undergoing menopause have no control over their hot flashes, which can happen often, last up to 20 minutes, and be debilitating to daily activities. Nisa EFFECT has created a cooling bra so that the 80 percent of women who experience hot flashes during menopause can have a discrete way to cool down.

FreeFuse

Five hundred hours of video content is uploaded every minute, and the sheer oversaturation of the industry makes growing an audience extremely difficult for content producers. Interactive video platform FreeFuse, an OwlSpark company, wants to flip the script and allow content creators to see what its audient wants to see in terms of content.

Morpheus Health

Pharmaceutical companies don't make it easy to find out about side effects medicines can have on its users. Morpheus Health, an OwlSpark company, uses data and patient information to better customize and predict potential side effects a medicine can have. Morpheus's results don't replace prescriptions or doctor consultations, but instead allow the patient to take that information into the consultation room.

Phase Filter

​Changing the air filters is an easily forgotten chore that, if undone, can cause unnecessary air quality issues and a higher electricity bill for homeowners. Phase Filter has designed a self-scrolling air filter that's easy to install and only needs to be changed once a year,

Bloodhound

The OwlSpark and RED Labs summer programs are meant to help early-stage startups figure out their market need and determine whether or not their product is a viable business. The Bloodhound team explains how they came up with their idea for a software that helps detect bleed in surgeries, and then how they realized, after research and mentorship through the program, that it wasn't an idea worth pursuing. Doctors need more help with stopping bleeds than finding them.

Crew Trace Solutions

The Navy needs an upgrade to their accountability practice. That's where Crew Trace Solutions, an OwlSpark company run by two military veterans, comes in. The technology mirrors something like EZ-Tag where personnel onboard are tracked throughout the ship as they pass through sensors set up in doorways around the boat.

VAYL

Everyone dreads the discomfort and disappointment that usually comes with dental appointments. The oral hygiene tools on the market today aren't cutting it, says the VAYL team, a RED Labs company. VAYL has created a device that brushes the entire mouth in an optimal way for time and for cavity prevention.

MoodyCorium

Finding the right moisturizer is a costly and exhausting industry for women. MoodyCorium, an OwlSpark company, is working on a solution so that women can navigate the hundreds of products available on the market.

ElastEye

Half of the glaucoma patients could have had their disease prevented by better diagnostics — and that's exactly what ElastEye has developed. The RED Labs company has created a non-invasive, early detection device that determines the elasticity of the eye.

BitGrange

Supporting local farmers can be hard — it might raise the price of produce for consumers while orders tend to be smaller than farmers prefer. BItGrange, an OwlSpark company, created an e-commerce platform to allow consumers to go in on purchases together to create a win-win situation for both sides of the transaction.

dext

Simple daily tasks can be overwhelming to stroke survivors and the only solution is exercise and rehabilitation. Dext is a wearable tool to help take that exercise and rehab into a daily, easy to use setting.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup debuts bio-based 'leather' fashion collection in Milan

sustainable fashion

Earlier this month, Houston-based Rheom Materials and India’s conscious design studio Econock unveiled a collaborative capsule collection that signaled more than just a product launch.

Hosted at Lineapelle—long considered the global epicenter of the world's premier leather supply chain—in the vaulted exhibition halls of Rho-Fiera Milano, the collection centered around Rheom’s 91 percent bio-based leather alternative, Shorai.

It was a bold move, one that shifted sustainability from a concept discussed in panel sessions to garments that buyers could touch and wear.

The collection featured a bomber-style jacket, an asymmetrical skirt and a suite of accessories—all fabricated from Shorai.

The standout piece, a sculptural jacket featuring a funnel neck and dual-zip closure, was designed for movement, challenging assumptions about performance limitations in bio-based materials. The design of the asymmetrical skirt was drawn from Indian armored warrior traditions, according to Rheom, with biodegradable corozo fasteners.

Built as a modular wardrobe rather than isolated pieces, the collection reflects a shared belief between Rheom and Econock in designing objects that adapt to daily life, according to the companies.

The collection was born out of a new partnership between Rheom and Econock, focused on bringing biobased materials to the market. According to Rheom, the partnership solves a problem that has stalled the adoption of many next-gen textiles: supply chain friction.

While Rheom focuses on engineering scalable bio-based materials, New Delhi-based Econock brings the complementary design and manufacturing ecosystem that integrates artisans, circular materials and production expertise to translate the innovative material into finished goods.

"This partnership removes one of the biggest barriers brands face when adopting next-generation materials,” Megan Beck, Rheom’s director of product, shared in a news release. “By reducing friction across the supply chain, Rheom can connect brands directly with manufacturers who already know how to work with Shorai, making the transition to more sustainable materials far more accessible.”

Sanyam Kapur, advisor of growth and impact at Econock, added: “Our partnership with Rheom Materials represents the benchmark of responsible design where next-gen materials meet craft, creativity, and real-world scalability.”

Rheom, formerly known as Bucha Bio, has developed Shorai, a sustainable leather alternative that can be used for apparel, accessories, car interiors and more; and Benree, an alternative to plastic without the carbon footprint. In 2025, Rheom was a finalist for Startup of the Year in the Houston Innovation Awards.

Shorai is already used by fashion lines like Wuxly and LuckyNelly, according to Rheom. The company scaled production of the sugar-based material last year and says it is now produced in rolls that brands can take to market with the right manufacturer.

Houston startup debuts leather alternative fashion collection in Milan

Houston clean energy co. secures $100M to deploy tech on global scale

Going Global

Houston-based Utility Global has raised $100 million in an ongoing Series D round to globally deploy its decarbonization technology at an industrial scale.

The round was led by Ara Partners and APG Asset, according to a news release. Utility plans to use the funding to expand manufacturing, grow its teams and support its commercial developments and partnerships.

“This financing marks a critical step in Utility’s transition from a proven technology to full-scale global commercial execution,” Parker Meeks, CEO and president of Utility Global, said in the release. “Industrial customers are no longer looking for pilots or promises; they need deployable solutions that work within existing assets and deliver true economic industrial decarbonization today that is operationally reliable and highly scalable. Utility’s technology produces both economic clean hydrogen and capture-ready CO2 streams, and this capital enables us to scale and deploy that impact globally with speed, discipline, and rigor.”

Utility Global's H2Gen technology produces low-cost, clean hydrogen from water and industrial off-gases without requiring electricity. It's designed to integrate into existing industrial infrastructure in hard-to-abate assets in the steel, refining, petrochemical, chemical, low-carbon fuels, and upstream oil and gas sectors.

“Utility is tackling one of the most difficult challenges in the energy transition: decarbonizing hard‑to‑abate industrial sectors,” Cory Steffek, partner at Ara Partners and Utility Global board chair, said in the release. “What sets Utility apart is its ability to compete head‑to‑head with conventional fossil‑based solutions on cost and reliability, even as it materially reduces emissions. With this new funding, Utility is well-positioned for its next chapter of commercial growth while maintaining the technical excellence and capital discipline that have defined its development to date.”

Utility Global reached several major milestones in 2025. After closing a $53 million Series C, the company agreed to develop at least one decarbonization facility at an ArcelorMittal steel plant in Brazil. It also signed a strategic partnership with California-based Kyocera International Inc. to scale global manufacturing of its H2Gen electrochemical cells.

The company also partnered with Maas Energy Works, another California company, to develop a commercial project integrating Maas’ dairy biogas systems with H2Gen to produce economical, clean hydrogen.

"These projects were never intended to stand alone. They anchor a deep and growing pipeline of commercial projects now in development globally across steel, refining, chemicals, biogas and other hard-to-abate sectors worldwide, Meeks shared in a 2025 year-in-review note. He added that 2026 would be a year of "focused acceleration to scale."

---

This article originally appeared on EnergyCapitalHTX.com.

Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

  • 21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
  • 68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.